All posts by dksKDSd9889

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Demonstrates ongoing commitment to innovation in ophthalmics for Shire

P-321 is a Phase 2 investigational topical treatment for dry eye disease

Lexington, Massachusetts, and Durham, North Carolina, US – May 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

READ THE ENTIRE PRESS RELEASE HERE ►

Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference

Clinical Data to be presented for a novel device for transnasal delivery of a pulmonary aerosol in children with Cystic Fibrosis

Durham, NC (October 25, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.

READ THE ENTIRE PRESS RELEASE HERE ►

Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease

First Patient Enrolled in P-321-202 Clinical Trial

Durham, NC (July 26, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has initiated a phase 2 clinical trial of P-321 Ophthalmic Solution in patients with Dry Eye Disease (DED). P-321 is a potent inhibitor of the epithelial sodium channels (ENaC) on the ocular surface, and is expected to restore the tear film on the ocular surface in those patients with dry eye disease. Earlier this year the results of a Phase 1/2a safety, tolerability, and pharmacokinetics study in subjects with dry eye were presented.

READ THE ENTIRE PRESS RELEASE HERE ►

Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)

Data on P-321 from clinical research to be presented on May 3rd

Durham, NC (May 2, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the presentation of a poster containing clinical data for the development stage dry eye treatment P-321. The presentation is a review of the results from a clinical trial of P-321 versus placebo in patients with dry eye disease and will be presented at the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington on May 3rd, 2016.

READ THE ENTIRE PRESS RELEASE HERE ►

Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases

LIBOURNE FRANCE and DURHAM NC (January 19, 2016) — Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.

READ THE ENTIRE PRESS RELEASE HERE ►